Astrazeneca Pursues $400B Merger Talks With Bristol Myers Squibb

WHO:

NY Post - AstraZeneca and Bristol Myers Squibb are the companies involved in the merger talks.

Bloomberg Markets - AstraZeneca Plc and Bristol Myers Squibb Co. are the entities exploring the acquisition.

WHAT:

NY Post - The potential deal could create one of the world's biggest pharmaceutical groups.

Bloomberg Markets - The merger is described as a megadeal with a combined value of nearly $400 billion.

WHERE:

Bloomberg Markets - The companies are based in the pharmaceutical industry, which operates globally.

WHEN:

NY Post - The merger talks are currently ongoing, with no specific future date mentioned for completion.

WHY:

Bloomberg Markets - The motivation behind the merger is to create one of the largest drugmakers in the world.

HOW:

Bloomberg Markets - The acquisition is being explored through discussions between the two companies.

(UPDATED August 2, 2026 23:51 UTC)

AstraZeneca and Bristol Myers Squibb are currently in talks about a potential merger that could create one of the world's largest pharmaceutical groups. This megadeal is estimated to be valued at nearly $400 billion, as the companies aim to solidify their positions in the global pharmaceutical industry. Discussions are ongoing, but no specific timeline has been provided for when the deal might be finalized.